LMK-235

• Description:

  LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC50s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/LMK-235.html

• Purity:

  99.61

• Solubility:

  DMSO : 175 mg/mL (ultrasonic)

• Smiles:

  O=C (NOCCCCCC (NO) =O) C1=CC (C) =CC (C) =C1

• Molecular Formula:

  C15H22N2O4

• Molecular Weight:

  294.35

• Precautions:

  H302

• References & Citations:

  [1]Marek L, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013 Jan 24;56 (2) :427-36.|[2]Li A, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer. Oncotarget. 2016 Jun 21;7 (25) :37966-37978.|[3]Trazzi S, et al. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder. Hum Mol Genet. 2016 Sep 15;25 (18) :3887-3907.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC11; HDAC2; HDAC4; HDAC5; HDAC6; HDAC8

• CAS Number:

  1418033-25-6